Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders

Autor:	Bruce Strober, April Armstrong, Simone Rubant, Manish Patel, Tianshuang Wu, Huzefa Photowala, Jeffrey Crowley
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	psoriasis incomplete responder switching treatments risankizumab Dermatology RL1-803
Zdroj:	Journal of Dermatological Treatment, Vol 33, Iss 7, Pp 2991-2996 (2022)
Druh dokumentu:	article
ISSN:	0954-6634 1471-1753 09546634 78854342
DOI:	10.1080/09546634.2022.2095328
Popis:	Background Psoriasis is often treated with biologic therapies. While many patients see improvement in their symptoms with treatment, some achieve only partial success. Objective and Methods In this post-hoc analysis we assess Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) results from patients who switched to RZB due to suboptimal results that originally received ADA (N = 53, IMMvent NCT02694523) or UST (N = 172, UltIMMa-1 [NCT02684370], UltIMMa-2 [NCT02684357]). Results For patients originally treated with ADA, after three doses of RZB, 83.3% of PASI 50 to
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/b960321c78854342a658ec3be18dff02 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.